CD95-dependent T-cell killing by glioma cells expressing CD95 ligand: More on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain

被引:37
作者
Weller, M
Weinstock, C
Will, C
Wagenknecht, B
Dichgans, J
Lang, F
Gulbins, E
机构
[1] UNIV TUBINGEN,DEPT PHYSIOL,D-72076 TUBINGEN,GERMANY
[2] UNIV TUBINGEN,DEPT NEUROL,D-72076 TUBINGEN,GERMANY
[3] UNIV TUBINGEN,DEPT TRANSFUS MED,D-72076 TUBINGEN,GERMANY
关键词
apoptosis; glioma; lymphocytes; fas/CD95/APO-1;
D O I
10.1159/000154883
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Apparent failure of tumor-infiltrating lymphocytes to induce significant tumor cell death has been documented in numerous malignancies including malignant gliomas, T-cell suppression in glioma patients has commonly been attributed to soluble immunosuppressive factors such as transforming growth factor-beta (TGF-beta). However, more recently CD95 ligand expressed on tumor cells has also been shown to induce T-cell apoptosis, Here, we report that human malignant glioma cells express CD95 ligand and kill human Jurkat T cells via CD95/CD95 ligand interactions, T-cell apoptosis is blocked when interactions of CD95 ligand expressed on glioma cells with CD95 expressed on T cells are inhibited competitively by soluble CD95 protein, Although glioma cells coexpress CD95 ligand and CD95 and are highly sensitive to CD95 antibody or soluble CD95 ligand, they neither commit suicide nor fratricide, We conclude that (i) susceptibility to CD95-mediated apoptosis involves crucial regulatory mechanisms other than levels of CD95 and CD95 ligand expression, and (ii) multiple mechanisms including soluble factors such as TGF-beta and cell-derived signals such as CD95 ligand-induced signalling mediate immune escape of malignant brain tumors.
引用
收藏
页码:282 / 288
页数:7
相关论文
共 18 条
[1]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[2]  
EHL AR, 1995, EUR J IMMUNOL, V25, P2253
[3]   Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover [J].
French, LE ;
Hahne, M ;
Viard, I ;
Radlgruber, G ;
Zanone, R ;
Becker, K ;
Muller, C ;
Tschopp, J .
JOURNAL OF CELL BIOLOGY, 1996, 133 (02) :335-343
[4]   FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE [J].
GRIFFITH, TS ;
BRUNNER, T ;
FLETCHER, SM ;
GREEN, DR ;
FERGUSON, TA .
SCIENCE, 1995, 270 (5239) :1189-1192
[5]   Physiology of Fas-induced programmed cell death [J].
Gulbins, E ;
Szabo, I ;
Lang, F .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 1996, 6 (06) :361-375
[6]   FAS-INDUCED APOPTOSIS IS MEDIATED VIA A CERAMIDE-INITIATED RAS SIGNALING PATHWAY [J].
GULBINS, E ;
BISSONNETTE, R ;
MAHBOUBI, A ;
MARTIN, S ;
NISHIOKA, W ;
BRUNNER, T ;
BAIER, G ;
BAIERBITTERLICH, G ;
BYRD, C ;
LANG, F ;
KOLESNICK, R ;
ALTMAN, A ;
GREEN, D .
IMMUNITY, 1995, 2 (04) :341-351
[7]   Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].
Hahne, M ;
Rimoldi, D ;
Schroter, M ;
Romero, P ;
Schreier, M ;
French, LE ;
Schneider, P ;
Bornand, T ;
Fontana, A ;
Lienard, D ;
Cerottini, JC ;
Tschopp, J .
SCIENCE, 1996, 274 (5291) :1363-1366
[8]   The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand [J].
OConnell, J ;
OSullivan, GC ;
Collins, JK ;
Shanahan, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (03) :1075-1082
[9]   Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics [J].
Roth, W ;
Fontana, A ;
Trepel, M ;
Reed, JC ;
Dichgans, J ;
Weller, M .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 44 (01) :55-63
[10]   CD95/Fas/Apo-1-mediated signal transduction [J].
Schlottmann, K ;
Coggeshall, KM .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 1996, 6 (06) :345-360